<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079791</url>
  </required_header>
  <id_info>
    <org_study_id>GE MucI001-16</org_study_id>
    <nct_id>NCT03079791</nct_id>
  </id_info>
  <brief_title>Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT</brief_title>
  <acronym>IMPROVE-OCT</acronym>
  <official_title>Prospective Registry of Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LMU Klinikum</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LMU Klinikum</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to use the high resolution of optical coherence tomography to assess&#xD;
      the prevalence of different types of cardiac allograft vasculopathy (CAV) in cardiac&#xD;
      transplanted patients and correlate those results with the level of immunosuppression&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CAV is the most common reason for retransplantation at &gt;1 year and one of the main risk&#xD;
      factors for mortality after cardiac transplantation. For this registry, patients planned to&#xD;
      undergo coronary angiography either as a part of routine follow-up to screen for relevant&#xD;
      cardiac allograft vasculopathy or because of clinical suspicion of relevant cardiac allograft&#xD;
      vasculopathy will be considered eligible.&#xD;
&#xD;
      Since the &quot;Transplant Care Guidelines of 2010&quot; recommend the use of intracoronary imaging&#xD;
      during angiographic follow-up in patients after heart transplantation to recognize CAV as&#xD;
      early as possible, OCT has become integral part of the CAV diagnostic in our center. Through&#xD;
      its high resolution OCT (so called virtual histology) provides the earliest possible&#xD;
      diagnosis of CAV as well as new insights into the differentiation of CAV types. We aim to&#xD;
      correlate the findings of OCT with the level of immunosuppression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>CAV patterns</measure>
    <time_frame>2 years</time_frame>
    <description>Evaluation of CAV with optical coherence tomography imaging in different follow-up timepoints according to the Heart Transplant Care guidelines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunosuppression compliance</measure>
    <time_frame>2 years</time_frame>
    <description>Association between pattern of CAV and the appropriateness of immunosuppression as measured regularly in routine laboratory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>combined ischemic events</measure>
    <time_frame>2 years</time_frame>
    <description>Combined incidence of death, re-transplantation, myocardial infarction, stroke and coronary revascularization</description>
  </secondary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Transplant; Failure, Heart</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients after successful cardiac transplantation at the time of coronary angiography as&#xD;
        part of routine follow-up after cardiac transplantation or as invasive diagnostic tool in&#xD;
        case of clinical suspicion of cardiac allograft vasculopathy and indication for&#xD;
        intravascular imaging according to guidelines.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients after cardiac transplantation undergoing planed routine angiographic&#xD;
             examination and intracoronary imaging.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Hemodynamic and/or electric instability&#xD;
&#xD;
          -  Chronic kidney failure with glomerular filtration rate &lt; 30 ml/min&#xD;
&#xD;
          -  Pregnant or breastfeeding women&#xD;
&#xD;
          -  Incapacity of providing informed consent&#xD;
&#xD;
          -  If in the investigator's opinion the patient has (a) co-morbid condition(s) that could&#xD;
             limit the patient's ability to participate in the study or impact the scientific&#xD;
             integrity of the study&#xD;
&#xD;
          -  Any contraindication to intracoronary imaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LMU Munich</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Munich University Hospital</name>
      <address>
        <city>Munich</city>
        <state>Bavaria</state>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 27, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2017</study_first_posted>
  <last_update_submitted>February 23, 2021</last_update_submitted>
  <last_update_submitted_qc>February 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LMU Klinikum</investigator_affiliation>
    <investigator_full_name>Steffen Massberg</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>OCT</keyword>
  <keyword>cardiac allograft vasculopathy</keyword>
  <keyword>CAV</keyword>
  <keyword>intravascular imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

